Renin: friend or foe?

被引:72
作者
Brown, Morris J. [1 ]
机构
[1] Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England
关键词
D O I
10.1136/hrt.2006.107706
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renin maintains blood pressure through vasoconstriction when there is inadequate salt to maintain volume. In populations where blood pressure is more often high than low, and vascular death more common than haemorrhage or dehydration, therapeutic reductions in renin secretion or response are valuable. Whether long- term benefits are due entirely to blood pressure reduction remains unproved. The pathway can be blocked at its rate- limiting step ( beta blockade or direct renin inhibition), the synthesis of the active product, angiotensin II, or at the receptor for angiotensin. Because renin and sodium are the two main factors in blood pressure control, and renin levels vary inversely with sodium load, blood pressure control requires a combination of natriuresis and blocking the consequential increase in renin activity. Being a large and stable molecule, renin is among the easiest and cheapest of hormone measurements. Understanding the simple biochemistry and physiology of renin permits optimal use of the drugs acting to raise or suppress this hormone.
引用
收藏
页码:1026 / 1033
页数:8
相关论文
共 82 条
[11]   ESSENTIAL HYPERTENSION - RENIN AND ALDOSTERONE, HEART ATTACK AND STROKE [J].
BRUNNER, HR ;
BUHLER, FR ;
BARD, RH ;
BAER, L ;
GOODWIN, FT ;
NEWTON, MA ;
KRAKOFF, LR ;
LARAGH, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1972, 286 (09) :441-+
[12]   Hyperaldosteronism among with resistant black and white subjects hypertension [J].
Calhoun, DA ;
Nishizaka, MK ;
Zaman, MA ;
Thakkar, RB ;
Weissmann, P .
HYPERTENSION, 2002, 40 (06) :892-896
[13]   RELATION BETWEEN DOSE OF BENDROFLUAZIDE, ANTIHYPERTENSIVE EFFECT, AND ADVERSE BIOCHEMICAL EFFECTS [J].
CARLSEN, JE ;
KOBER, L ;
TORPPEDERSEN, C ;
JOHANSEN, P .
BRITISH MEDICAL JOURNAL, 1990, 300 (6730) :975-978
[14]   Effect of inhibitors of the renin-angiotensin system and other anti hypertensive drugs on renal outcomes: systematic review and meta-analysis [J].
Casas, JP ;
Chua, WL ;
Loukogeorgakis, S ;
Vallance, P ;
Smeeth, L ;
Hingorani, AD ;
MacAllister, RJ .
LANCET, 2005, 366 (9502) :2026-2033
[15]   Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases [J].
Cesari, M ;
Rossi, GP ;
Pessina, AC .
JOURNAL OF HYPERTENSION, 2002, 20 (05) :793-799
[16]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[17]  
Cockcroft JR, 2002, LANCET, V359, P2202, DOI 10.1016/S0140-6736(02)09075-X
[18]   Mutations in the Na-Cl cotransporter reduce blood pressure in humans [J].
Cruz, DN ;
Simon, DB ;
Nelson-Williams, C ;
Farhi, A ;
Finberg, K ;
Burleson, L ;
Gill, JR ;
Lifton, RP .
HYPERTENSION, 2001, 37 (06) :1458-1464
[19]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[20]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906